Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Rhea-AI Summary

Oncocyte Corp (Nasdaq: OCX) has announced its participation in BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference taking place on February 11-12, 2025, in Snowbird, Utah. CEO Josh Riggs and CFO Andrea James will represent the diagnostics technology company at the event, where they will conduct one-on-one meetings with potential investors.

Interested investors attending the conference are encouraged to contact BTIG directly to schedule meetings with Oncocyte's leadership team.

February 11-12, 2025, Snowbird, Utah

IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. Oncocyte will host one-on-one meetings with interested investors.

Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to schedule.

Event: BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference 2025
Dates: February 11-12, 2025
Location: Snowbird, Utah, USA

About Oncocyte
Oncocyte is a leading diagnostics technology company. The company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:

VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/
GraftAssure™ - https://oncocyte.com/graftassure/
DetermaIO™ - https://oncocyte.com/determa-io/
DetermaCNI™ - https://oncocyte.com/determa-cni/

VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com

FAQ

When and where is Oncocyte (OCX) participating in the BTIG MedTech Conference 2025?

Oncocyte (OCX) is participating in the BTIG MedTech Conference on February 11-12, 2025, in Snowbird, Utah.

Who will represent Oncocyte (OCX) at the BTIG MedTech Conference 2025?

CEO Josh Riggs and CFO Andrea James will represent Oncocyte at the conference.

How can investors meet with Oncocyte (OCX) management at the BTIG Conference?

Investors attending the conference can contact BTIG directly to schedule one-on-one meetings with Oncocyte management.

What type of meetings will Oncocyte (OCX) conduct at the BTIG Conference 2025?

Oncocyte will conduct one-on-one meetings with interested investors at the conference.